Mycoplasma hyopneumoniae attenuated strain and application thereof in preparation of attenuated vaccines
A technology for mycoplasma hyopneumoniae and attenuated vaccines, which is applied to attenuated strains of mycoplasma hyopneumoniae and its application in the preparation of attenuated vaccines, and can solve the problems of unsatisfactory protective effects of inactivated vaccines, undetectable serum antibodies, and difficulty in clinical application. , to achieve good protective effect, good immune effect and strong immune protection
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0024] The Mycoplasma hyopneumoniae ES-2L strain of the present invention is based on the local clinical isolation of the highly virulent strain ES-2 strain (preservation number CCTCC NO: M 2018570), which is continuously passed in vitro for 200 generations. The specific subculture process is as follows: resuscitate and activate the frozen ES-2 strain, and use the resuscitated and activated bacterial liquid as the P1 generation; After 2 to 3 days of cultivation in the environment, harvest it as the P2 generation; carry out continuous subculture in this way, and when it reaches the 197th generation, spread the harvested bacterial liquid on the improved Friis solid medium, and place it in an environment of 37°C and 5% carbon dioxide After 7-10 days of medium culture, pick a single colony under a low-magnification microscope and insert it into Friis liquid medium for culture; carry out 3 consecutive clone purification and identification in this way, and name the bacterial liquid o...
Embodiment 2
[0036] The P1 generation and ES-2L strain of Mycoplasma hyopneumoniae ES-2 strain were evaluated for virulence. Twelve 25-day-old Landrace male pigs and Large White sow binary hybrid pigs were divided into three groups, A, B, and C, with 4 pigs in each group. Among them, the P1 generation Mycoplasma hyopneumoniae of the P1 generation was injected intratracheally in the A group. Group B was injected with intratracheal injection of Mycoplasma hyopneumoniae ES-2L strain, and group C was injected with normal saline (blank control group). The attacking doses of group A and group B were both 7×10 8 CCU. After the challenge, the animals were dissected after 42 days of observation, during which the body temperature, body weight and clinical symptoms were observed.
[0037] The virulence evaluation experiment showed that there was no increase in body temperature in each group after the challenge; the body weight was measured and the daily average gain was calculated. -2L strain chal...
Embodiment 3
[0043] The Mycoplasma hyopneumoniae ES-2L strain was cultivated to a stable phase in an environment of 37°C and 5% carbon dioxide with the improved Friis liquid medium, and the bacterial liquid was harvested, and the harvested bacterial liquid was diluted with the improved Friis liquid medium to adjust the titer to 1 ×10 7 CCU / mL, prepared into attenuated vaccine. Fifteen 14-day-old Landrace boars and Large White sows were divided into groups A, B, and C, with 5 pigs in each group. Group A is the intramuscular injection immunization group, 14 days old neck intramuscular injection immunization once, 14 days after the first immunization, booster immunization once with the same dose and procedure, each time 2mL / head; B group is the normal saline immunization group (challenge virus) control group), and group C was the blank control group. Immunization dose is 2×10 7 In CCU, except for the blank control group, the other two groups received intratracheal injection of 7 mL of viru...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com